Regulatory Expertise FDAMap is a specialized CRO with deep FDA regulatory know-how, offering end-to-end support from strategy to submission that can be leveraged to accelerate client trials and reduce regulatory risk.

Mid-Market Focus With 11-50 employees and revenue in the 10M-25M range, FDAMap targets growing biotech, pharma, and medical device companies seeking flexible, high-quality CRO services without engaging in large-biomass vendor commitments.

Comprehensive Services The full-service model covering regulatory strategy, study design, data management, biostatistics, and submissions presents cross-sell opportunities across multiple trial phases and therapeutic areas.

Tech-Enabled Ops Utilization of AWS, analytics tooling, and modern client interfaces (Zendesk, iCIMS, CRMs) suggests efficiency, scalable project delivery, and potential to offer digital trial acceleration and compliant data handling.

Growth Adjacent Markets Comparable CROs serve large pharma, but FDAMap’s niche positioning and growth potential in biotech and medical devices indicate opportunities to win new clients preparing for regulatory milestones or expedited submissions.